As of Nov 25
| +0.59 / +4.88%|
The 5 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 33.00, with a high estimate of 78.91 and a low estimate of 25.00. The median estimate represents a +160.25% increase from the last price of 12.68.
The current consensus among 5 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.